Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (T-LLy)

NCT06934382 is registered in ClinicalTrials.gov with Stephan Grupp MD PhD as lead sponsor.

NCT NCT06934382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06934382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (T-LLy)
Lead sponsor
Stephan Grupp MD PhD
Phase
Phase 1
Overall status
Recruiting
Start date
April 29, 2025
Completion date
May 30, 2031
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia/lymphoma